CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Subsidiary of CSPC Pharmaceutical Group (1093) · China
Assets
(4 total)
4Total Assets
0Approved
4Phase 3 / Filed
0Phase 1–2 / Early
7Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Microtubules (tubulin)Small molecule | Non-Small Cell Lung CancerBreast Cancer HER2-Positive Breast Cancer | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung CancerCervical Cancer | |
| Phase 3 | mTOR (mechanistic target of rapamycin complex 1), via FKBP-12Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaPrurigo Nodularis |
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Docetaxel (HB1801)Phase 2Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Est. primary completion 2026-12-25 · NCT06525350 · CT.gov ↗
What to watch
2027 (3)
2028 (2)
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
18 August 2026Filing acceptedDocetaxel (HB1801)NMPA accepted the NDA for anbenitamab plus HB1801 in first-line HER2-positive advanced breast cancer, with priority review
CN, NMPA · Source ↗
4 August 2026Filing acceptedDocetaxel (HB1801)NMPA accepts the NDA for anbenitamab (KN026) with docetaxel for injection (albumin-bound) (HB1801) as neoadjuvant therapy, with priority review
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
27 July 2026Filing acceptedSirolimus for Injection (Albumin-Bound) (HB1901)NMPA accepts the HB1901 new drug application, with Priority Review
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
CSPC Pharmaceutical Group Limited · Source ↗
20 April 2026Topline resultSirolimus for Injection (Albumin-Bound) (HB1901)Pivotal Phase Ib/III HB1901-004 study in advanced malignant PEComa met its primary endpoint
CSPC Pharmaceutical Group · Source ↗
CN, NMPA · Keymed Biosciences · Source ↗
CN, NMPA · Keymed Biosciences · Source ↗
28 April 2024Topline resultstapokibartPhase III PHECDA (NCT05908032) in seasonal allergic rhinitis met its primary endpoint
Keymed Biosciences Inc. · Source ↗
Financial reports
No financial reports recorded.